AVTR.NYSEAvantor, INC

Form 4: Avantor CEO Michael Stubblefield Reports Stock and Option Grants

Sentiment:

SEC Form 4


Avantor's CEO, Michael Stubblefield, reported the acquisition of restricted stock units and stock options, along with adjustments to his existing holdings.

Summary

  • On February 23, 2024, Michael Stubblefield, the President & CEO of Avantor, Inc., reported transactions involving Avantor's common stock and stock options.
  • Stubblefield acquired 107,802 shares of common stock through a grant of restricted stock units, which will vest in three equal annual installments starting February 23, 2025.
  • He also acquired 263,558 stock options with an exercise price of $24.35, vesting in three equal installments beginning February 23, 2025, and expiring on February 24, 2034.
  • Following these transactions, Stubblefield directly owns 1,219,553 shares of Avantor common stock.
  • He also indirectly owns 156,588 shares through a Grantor Retained Annuity Trust and 469,500 shares held by a family trust, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

  • The grant of restricted stock units and stock options to the CEO aligns his interests with those of the shareholders.
  • The vesting schedule of the grants encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock and option grants.

Industry Context

Stock and option grants are a common practice in the industry to incentivize and retain key executives.

Comparison to Industry Standards

  • Stock option and restricted stock unit grants are standard compensation practices for CEOs in publicly traded companies, particularly in the life sciences and technology sectors.
  • Companies like Thermo Fisher Scientific and Danaher also utilize similar equity-based compensation to align executive incentives with shareholder value.

Stakeholder Impact

  • The stock and option grants align the CEO's interests with those of the shareholders, potentially driving long-term value creation.
  • Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

DateDescription
02/23/2024Date of transaction: grant of restricted stock units and stock options.
02/23/2025First vesting date for the restricted stock units and stock options.
02/24/2034Expiration date for the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.